Sanofi India div shr 48 rupees

Sanofi India div shr 48 rupees

Sanofi India Recommends Final Dividend of ₹48 per Share Amid Strong Q4 and Full-Year Performance

Sanofi India Ltd’s board has recommended a final dividend of ₹48 per equity share for the financial year ended December 31, 2025, bringing the total annual dividend to ₹123 per share when combined with the interim dividend of ₹75 per share declared in October 2025. The final dividend requires shareholder approval at the 70th Annual General Meeting.

The company reported robust financial results for Q4 FY2025, with revenue rising 47% year-on-year to ₹251 crore. Domestic sales grew 23%, driven by the relaunch of previously recalled products, while export sales surged 9.3 times due to a low base. Profit after tax (PAT) for the quarter increased 50% to ₹66.5 crore.

For the full fiscal year 2025, Sanofi India’s revenue reached ₹878.4 crore, reflecting a 21% annual increase. Domestic sales rose 7%, and export sales grew 158% on a low base. PAT for the year climbed 33% to ₹240.1 crore, supported by disciplined cost management and an improved product mix.

The board also announced leadership changes, including the appointment of Rajani Kesari as an independent director and Sudipta Chakraborty as a whole-time director, effective April 1, 2026, and March 1, 2026, respectively, subject to shareholder approval. Rodolfo Hrosz resigned as a non-executive director effective February 28, 2026.

Himanshu Bakshi, Managing Director, attributed the performance to the company’s "strength of core portfolio and disciplined execution of the growth agenda," highlighting consecutive double-digit domestic sales growth and export contributions.

Shares of Sanofi India closed at ₹4,142.80 on February 25, 2026, up 1.60% on the BSE. The proposed dividend underscores the company's focus on shareholder returns amid expanding operations, including plans to increase its workforce to over 4,500 employees.

Word count: 300